VivoSim Labs, Inc. (VIVS)

VivoSim Labs, Inc. (VIVS) Healthcare & Pipeline Overview

VivoSim Labs, Inc. (VIVS) is a biotechnology company pioneering 3D human tissue platforms, including NovoGen Bioprinters, for disease modeling and drug development. Its lead candidate, FXR314, is in Phase 2/3 for inflammatory bowel disease and Phase 1 for liver fibrosis, positioning it at the forefront of regenerative medicine and therapeutic innovation.

What Is the Investment Thesis for VIVS?

VivoSim Labs, Inc. presents a research-stage investment profile centered on its proprietary 3D human tissue platform and lead drug candidate, FXR314. The company's core value proposition lies in its NovoGen Bioprinters, which enable the creation of complex 3D living tissues for disease modeling, potentially accelerating drug discovery and development. FXR314, currently in Phase 2/3 clinical trials for inflammatory bowel disease (ulcerative colitis) and having completed Phase 1 for liver fibrosis (steatohepatitis), represents significant potential catalysts for value creation. Positive clinical trial outcomes could substantially de-risk the asset and attract partnerships or accelerate market entry. The company's gross margin of 100.0% reflects its early-stage, R&D-focused operations, where direct product costs are minimal, while its -864.1% profit margin is characteristic of a biotechnology company heavily investing in research and clinical development. Strategic research collaborations with institutions like Yale School of Medicine further validate its technology and expand its scientific reach. The company's progress through clinical phases and the broader adoption of its bioprinting platform are key drivers for future valuation.

Based on FMP financials and quantitative analysis

VIVS Key Highlights

• Market Capitalization currently stands at $0.00 billion, indicating a micro-cap or pre-revenue stage for the company.
• Profit Margin of -864.1% reflects significant investment in research and development, typical for a biotechnology company in clinical trial phases.
• Gross Margin of 100.0% suggests that direct costs of goods sold are minimal or non-existent, consistent with a company primarily focused on R&D and intellectual property development.
• A Beta of 1.41 indicates higher volatility compared to the broader market, which is common for early-stage biotechnology firms with significant clinical trial dependencies.
• The company operates with a lean team of 14 employees, focusing resources on specialized R&D and clinical development activities.

Who Are VIVS's Competitors?

VIVS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VIVS's Key Strengths?

• Proprietary 3D human tissue platform and NovoGen Bioprinters offer advanced disease modeling capabilities.
• Lead candidate FXR314 is in advanced Phase 2/3 clinical trials for inflammatory bowel disease, indicating significant progress.
• Established research collaborations with reputable academic institutions enhance scientific credibility and potential applications.
• High gross margin (100.0%) reflects an asset-light R&D focus on intellectual property and clinical development.
• Focus on unmet medical needs in IBD and liver fibrosis markets.

What Are VIVS's Weaknesses?

• Negative profit margin (-864.1%) indicates substantial cash burn typical of early-stage biotech, requiring ongoing funding.
• Small employee base (14 employees) may limit the scope and speed of multiple parallel development programs.
• Reliance on the success of a limited number of drug candidates (FXR314) for future commercial viability.
• Market capitalization of $2.57M suggests a pre-revenue or very early commercial stage, with inherent financial risks.
• High beta (1.41) indicates significant stock price volatility, which can be a concern for investors.

What Could Drive VIVS Stock Higher?

• Announcement of Phase 2/3 clinical trial results for FXR314 in inflammatory bowel disease, which could significantly impact market perception and future development.
• Initiation of Phase 2 clinical trials for FXR314 in liver fibrosis (steatohepatitis), marking progression in this therapeutic area.
• Expansion of research collaborations for NovoGen Bioprinters, potentially leading to new applications, validation, or licensing agreements.
• Potential strategic partnerships or licensing deals related to FXR314 or the 3D tissue platform, offering non-dilutive funding and broader market reach.

What Are the Key Risks for VIVS?

• Negative return on equity (-15.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failure or unexpected adverse events for FXR314 in either inflammatory bowel disease or liver fibrosis, which could halt development and significantly impact the company's prospects.
• Significant capital requirements to fund ongoing research and development, clinical trials, and potential commercialization efforts, leading to potential future equity dilution.
• Regulatory hurdles and delays in gaining approval from health authorities for FXR314, extending time-to-market and increasing development costs.
• Intense competition within the biotechnology sector for both 3D bioprinting technology and therapeutic candidates targeting IBD and liver fibrosis.
• Challenges in scaling up manufacturing or commercialization of FXR314 or the NovoGen Bioprinters platform, should they reach market readiness.

What Are the Growth Opportunities for VIVS?

• FXR314 for Inflammatory Bowel Disease (IBD): The lead candidate, FXR314, is in Phase 2/3 clinical trials for IBD, specifically ulcerative colitis. The global market for IBD treatments is substantial, projected to reach over $25 billion by the late 2020s, driven by increasing prevalence and demand for more effective therapies. Successful progression through these advanced clinical stages and eventual market approval for FXR314 could unlock a significant revenue stream for VivoSim Labs, positioning it as a key player in managing chronic inflammatory conditions. The timeline for this opportunity extends through the late 2020s and early 2030s, contingent on trial success and regulatory approvals.
• FXR314 for Liver Fibrosis (Steatohepatitis): FXR314 has completed Phase 1 clinical trials for liver fibrosis, with a focus on steatohepatitis, a condition often associated with Non-Alcoholic Steatohepatitis (NASH). The NASH market alone is estimated to exceed $20 billion by the early 2030s, representing a vast unmet medical need. Advancing FXR314 through subsequent clinical phases for this indication could provide VivoSim Labs with access to another large therapeutic market. This opportunity is in an earlier stage compared to IBD, with a potential market entry timeline extending into the early to mid-2030s, pending further clinical development and regulatory milestones.
• Expansion of NovoGen Bioprinters Platform Adoption: VivoSim Labs' proprietary NovoGen Bioprinters and associated 3D human tissue platform offer a significant growth avenue through broader adoption in pharmaceutical research, academic institutions, and contract research organizations. These bioprinters provide more accurate and predictive models for drug discovery, toxicology testing, and disease modeling compared to conventional methods. Licensing or selling these platforms, along with bio-inks and technical support, could establish a recurring revenue stream. The market for 3D bioprinting technology in research is continuously expanding, with growth expected over the next decade as the technology matures and its benefits become more widely recognized.
• Strategic Research Collaborations and Partnerships: The company's existing research collaborations with institutions like Yale School of Medicine and the University of Virginia validate its technology and provide avenues for further scientific advancement. Expanding these partnerships to include more pharmaceutical companies or larger biotech firms could lead to co-development agreements, licensing deals, or even acquisition opportunities. Such collaborations can provide non-dilutive funding, access to broader research expertise, and accelerate the development of new applications for VivoSim's 3D tissue platform. This growth driver is ongoing and can yield results throughout the late 2020s and beyond.
• Development of New Therapeutic Indications for 3D Tissues: Beyond FXR314, VivoSim Labs' core 3D human tissue platform has the potential to be applied to a wide array of other diseases and therapeutic areas. The ability to recapitulate key aspects of human disease in a 3D environment opens doors for discovering and developing novel treatments across oncology, neurology, cardiovascular diseases, and more. Investing in R&D to explore new applications for its bioprinted tissues could lead to the identification of additional drug candidates or the creation of new diagnostic tools, diversifying the company's pipeline and market reach over the long term, with opportunities emerging throughout the 2030s.

What Opportunities Does VIVS Have?

• Successful clinical trial outcomes for FXR314 could lead to market approval and significant revenue generation.
• Expansion of the NovoGen Bioprinters platform into broader research and drug discovery markets through licensing or sales.
• Formation of new strategic partnerships with larger pharmaceutical companies for co-development or commercialization.
• Application of 3D tissue technology to new therapeutic areas beyond IBD and liver fibrosis, diversifying the pipeline.
• Potential for the 3D tissue models to accelerate drug discovery, reducing costs and timelines for pharmaceutical partners.

What Threats Does VIVS Face?

• Clinical trial failures or delays for FXR314 could significantly impact the company's valuation and future prospects.
• Intense competition from other biotechnology companies developing novel therapies for IBD and liver fibrosis.
• Regulatory hurdles and lengthy approval processes inherent in drug development could delay market entry.
• Need for substantial additional funding to complete clinical trials and commercialize products, potentially leading to dilution.
• Technological obsolescence or emergence of superior 3D bioprinting technologies from competitors.

What Are VIVS's Competitive Advantages?

• Proprietary NovoGen Bioprinters and associated 3D human tissue platform, representing advanced bioprinting technology.
• Clinical trial progress with lead candidate FXR314, particularly its advancement to Phase 2/3 for IBD, indicating significant R&D investment and regulatory milestones achieved.
• Established research collaborations with prominent academic institutions like Yale School of Medicine, validating the scientific rigor and potential of its technology.
• Expertise in creating complex multicellular tissues that recapitulate human disease, offering a differentiated approach to drug discovery and development.
• Intellectual property surrounding its bioprinting methods, bio-inks, and therapeutic candidates.

What Does VIVS Do?

VivoSim Labs, Inc., incorporated in 2007 and headquartered in San Diego, California, is a biotechnology company dedicated to developing advanced 3D tissues that accurately replicate critical aspects of human disease. Originally known as Organovo Holdings, Inc., the company underwent a name change to VivoSim Labs, Inc. in April 2025, reflecting its evolving strategic focus. At the core of its operations is a proprietary 3D human tissue platform, which features NovoGen Bioprinters. These automated devices are engineered to fabricate complex 3D living tissues composed of mammalian cells, alongside related technologies essential for preparing bio-inks and bioprinting multicellular structures with intricate architectures. This platform is designed to provide more physiologically relevant models for drug discovery and disease research compared to traditional 2D cell cultures. VivoSim Labs' lead drug candidate, FXR314, represents a significant focus in its pipeline. This candidate is currently undergoing a Phase 2/3 clinical trial for the indication of inflammatory bowel disease, with a specific emphasis on ulcerative colitis, a chronic inflammatory condition affecting the colon. Additionally, FXR314 has successfully completed a Phase 1 clinical trial for the indication of liver fibrosis, specifically targeting steatohepatitis, a severe form of fatty liver disease. Beyond its internal drug development efforts, VivoSim Labs fosters crucial research collaborations. The company has established partnerships with prestigious institutions such as Yale School of Medicine, the Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia. These collaborations are centered on advancing the research and application of its NovoGen Bioprinters, further validating and expanding the potential uses of its innovative 3D tissue technology across various scientific and medical fields.

What Products and Services Does VIVS Offer?

• Develops proprietary 3D human tissue platforms for disease modeling and drug discovery.
• Manufactures NovoGen Bioprinters, automated devices for fabricating 3D living tissues from mammalian cells.
• Creates specialized bio-inks and related technologies for bioprinting multicellular tissues with complex architectures.
• Conducts clinical trials for its lead drug candidate, FXR314, for inflammatory bowel disease (ulcerative colitis).
• Advances FXR314 through clinical development for liver fibrosis (steatohepatitis).
• Engages in research collaborations with academic institutions to further develop and validate its NovoGen Bioprinters.
• Focuses on creating more physiologically relevant in vitro models to improve the predictability of drug candidates.

How Does VIVS Make Money?

• Primarily focused on research and development of its drug candidate FXR314, with future revenue expected from drug sales upon approval.
• Potential future revenue streams from the licensing or sale of its NovoGen Bioprinters and related bio-ink technologies to research institutions and pharmaceutical companies.
• Engages in research collaborations that may provide funding, intellectual property development, or access to broader scientific expertise.
• Aims to generate value through the successful progression of its clinical pipeline and the commercialization of its proprietary bioprinting platform.

What Industry Does VIVS Operate In?

VivoSim Labs, Inc. operates within the dynamic and rapidly evolving biotechnology industry, specifically focusing on the niche of 3D bioprinting and tissue engineering for drug discovery and therapeutic development. This segment of the healthcare sector is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles, but also by the potential for groundbreaking medical advancements. The market for 3D bioprinting in healthcare is projected to grow substantially, driven by the demand for more accurate disease models, personalized medicine, and regenerative therapies. VivoSim Labs differentiates itself through its proprietary NovoGen Bioprinters and related bio-ink technologies, aiming to create more physiologically relevant human tissue models than traditional methods. The competitive landscape includes other bioprinting companies, contract research organizations (CROs) offering advanced in vitro models, and pharmaceutical companies with internal drug discovery platforms. VivoSim's strategy of developing both a platform technology and a lead drug candidate (FXR314) positions it to potentially capture value from both technology licensing and therapeutic product sales within this innovative space.

Who Are VIVS's Key Customers?

• Academic research institutions and universities (for NovoGen Bioprinters and collaborations).
• Pharmaceutical and biotechnology companies (potential licensees/purchasers of bioprinters, or partners for drug development).
• Ultimately, patients suffering from inflammatory bowel disease and liver fibrosis, upon successful drug commercialization.
• Contract research organizations (CROs) seeking advanced in vitro models for drug testing.

FY2026 estForward Outlook

Wall Street analysts project VivoSim Labs, Inc. revenue of about $201K for fiscal 2026, with EPS near $-9.00.

F-Score 3/9Financial Health

VivoSim Labs, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

ROE -16%Key Financial Metrics

Return on equity for VivoSim Labs, Inc. stands at -15.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -17.6%, showing how much profit it generates from its asset base. A current ratio of 2.44 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -85.5%, the inverse of the P/E and a quick read on earnings relative to price.

VivoSim Labs, Inc. (VIVS) Valuation Context

Valued at $2.57M, VIVS is classified as a micro-cap stock. Relative to its peer group, VIVS's quantitative score of 19/100 is below the peer average of 76/100.

Company Profile

VivoSim Labs, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Keith E. Murphy. VIVS has traded publicly since 2012.

VIVS Financials

VIVS Latest News

No recent news available for VIVS.

VIVS Analyst Consensus

VIVS MoonshotScore

Common Questions About VIVS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources